文献速递骨软组织肉瘤与黑色素瘤

上皮样肉瘤中蒽环类、吉西他滨与帕唑帕尼的多中心病例系列研究

Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
PubMed 文献 · JAMA Oncol · 2018-09-13

这项回顾性多中心病例系列纳入1990至2016年间确诊的115例局部晚期或转移性上皮样肉瘤患者,评估蒽环类方案、吉西他滨方案和帕唑帕尼的疗效。蒽环类与吉西他滨方案的缓解率分别为22%和27%,中位PFS分别为6个月和4个月;帕唑帕尼未见客观缓解,中位PFS为3个月。

要点

  • 蒽环类方案缓解率22%,中位PFS 6个月,报告1例完全缓解
  • 吉西他滨方案缓解率27%,中位PFS 4个月,报告2例完全缓解
  • 帕唑帕尼组未见客观缓解,中位PFS 3个月

核心结论

  • 蒽环类与吉西他滨方案在上皮样肉瘤中显示中等活性,两者缓解率与PFS相近。
  • 帕唑帕尼在上皮样肉瘤中的价值较低。
  • 这些数据可作为上皮样肉瘤新药试验的基准。

研究设计与样本

  • 共纳入115例患者,全部经本地病理复核按最新标准确认诊断。
  • 中位年龄32岁(范围15-77岁),男性80例(70%),女性35例(30%)。
  • 中位随访34个月;按RECIST评估缓解,PFS与OS采用Kaplan-Meier法计算。

主要发现

  • 蒽环类方案缓解率22%,中位PFS 6个月,报告1例完全缓解。
  • 吉西他滨方案缓解率27%,报告2例完全缓解,中位PFS 4个月。
  • 帕唑帕尼组未见客观缓解,中位PFS 3个月。
  • 蒽环类组中,近端形态型缓解率26% vs 经典型19%,近端原发部位26% vs 远端18%,呈更高趋势。
  • 吉西他滨组中,经典型形态型缓解率30% vs 近端型22%,远端原发部位40% vs 近端14%,呈更高趋势。

关键数值与推荐

  • 蒽环类方案:缓解率22%,中位PFS 6个月。
  • 吉西他滨方案:缓解率27%,中位PFS 4个月。
  • 帕唑帕尼:无客观缓解,中位PFS 3个月。

临床怎么用

  • 对于晚期上皮样肉瘤,蒽环类或吉西他滨方案均可作为系统治疗选择。
  • 帕唑帕尼在该病中活性低,不宜作为优先选择。
  • 上述数据可用于与患者沟通预后及作为新药临床试验的历史对照参考。

局限性

  • 回顾性设计,存在选择偏倚与数据完整性限制。
  • 样本量小,各治疗组例数不均衡。
  • 部分患者接受超过1种治疗,可能影响结果解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this disease. OBJECTIVE: To report on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in patients with advanced ES. DESIGN, SETTING, AND PARTICIPANTS: Seventeen sarcoma reference centers in Europe, the United States, and Japan contributed data to this retrospective analysis of patients with locally advanced/metastatic ES diagnosed between 1990 and 2016. Local pathological review was performed in all cases to confirm diagnosis according to most recent criteria. EXPOSURES: All patients included in the study received anthracycline-based regimens, gemcitabine-based regimens, or pazopanib. MAIN OUTCOME AND MEASURES: Response was assessed by RECIST. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method. Classic and proximal subtypes were defined based on morphology (according to 2013 World Health Organization guidelines). RESULTS: Overall, 115 patients were included, 80 (70%) were men and 35 (30%) were women, with a median age of 32 years (range, 15-77 years). Of the 115 patients with ES, 85 were treated with anthracycline-based regimens, 41 with gemcitabine-based regimens, and 18 with pazopanib. Twenty-four received more than 1 treatment. Median follow-up was 34 months. Response rate for anthracycline-based regimens was 22%, with a median PFS of 6 months. One complete response (CR) was reported. A trend toward a higher response rate was noticed in morphological proximal type (26%) vs classic type (19%) and in proximal vs distal primary site (26% vs 18%). The response rate for gemcitabine-based regimens was 27%, with 2 CR and a median PFS of 4 months. In this group, a trend toward a higher response rate was reported in classic vs proximal morphological type (30% vs 22%) and in distal vs proximal primary site (40% vs 14%). In the pazopanib group, no objective responses were seen, and median PFS was 3 months. CONCLUSIONS AND RELEVANCE: This is the largest retrospective series of systemic therapy in ES. We confirm a moderate activity of anthracycline-based and gemcitabine-based regimens in ES, with a similar response rate and PFS in both groups. The value of pazopanib was low. These data may serve as a benchmark for trials of novel agents in ES.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Frezza AM, Jones RL, Lo Vullo S, et al. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. JAMA Oncol. 2018. PMID: 29800950. doi:10.1001/jamaoncol.2018.0219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。